// App-Quantinova.ai

: Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).

Researchers

Presenter

  • Aly-Khan A. Lalani

Principal Investigators

  • Wanling Xie

  • Ronan Flippot

  • John A. Steinharter

  • Lauren Christine Harshman

  • Bradley Alexander McGregor

  • Daniel Yick Chin Heng

  • Toni K. Choueiri

Medical Centers

  • Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada

  • Dana-Farber Cancer Institute, Boston, MA

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Tom Baker Cancer Center, Calgary, AB, Canada

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

  • Solid malignancies

Biomarkers

  • Vascular endothelial growth factor A

  • X-Ray Repair Cross Complementing 1

  • Body mass index

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved